Inclusion Criteria:

1. Patients with newly diagnosed histologically confirmed advanced stage (III & IV)
epithelial ovarian cancer, fallopian tube or peritoneal cancer. --OR-- Patients with
a suspected malignancy who are unsuitable candidates for surgery (i.e., those with
medical co-morbidities, massive effusions, or tumor burden such that an optimal
resection is unlikely) who undergo a core biopsy that is positive for malignancy.

2. Patients who have undergone tumor reduction must have either stage III suboptimal (>
2 cm residual) disease or stage IV disease.

3. Patients may have had no prior chemotherapeutic regimen.

4. Zubrod performance status of 0, 1, or 2.

5. Patients must have recovered from effects of recent surgery. They should be free of
significant infection.

6. Patients must have adequate: Bone marrow function: WBC >/= than 3,000/microlitre,
platelets > 100,000/microlitre, absolute neutrophil (ANC) count >/= than
1.5/microlitre. Renal function: Creatinine
7. Patients must have adequate: Neurologic function: Pre-existing peripheral neurologic
toxicity is allowed but limited to parasthesia and decreased vibratory sense without
motor weakness. Intermittent constipation managed with laxatives is allowed, without
evidence of bowel obstruction. Psychiatric function: Functions independently without
evidence of delirium, confusion, suicidal ideation, or untreated depression.

8. Patients who have signed an approved informed consent.

Exclusion Criteria:

1. Patients with borderline or grade 1 (low grade) tumors.

2. Patients who have received any prior cytotoxic chemotherapy or radiotherapy.

3. Patients with septicemia, severe infection, acute hepatitis, or gastrointestinal
bleeding at the time of protocol entry.

4. Patients with unstable angina or those who have had a myocardial infarction within
the past six months. Patients with evidence of abnormal cardiac conduction (e.g.,
bundle branch block, heart block, etc.) are eligible if their disease has been stable
for the past six months.

5. Patients whose circumstances do not permit completion of the study or the required
follow-up.

6. Patients with a history of another malignancy within 5 years. Patients who have had a
prior malignancy but remain continuously free of recurrent or persistent disease for
more than 5 years may be entered in the study after consultation with the study
chair.

7. Patients with significant pre-existing cardiac disease (NYHA class III-IV) will be
excluded.